Onconetix, Inc.
ONCOHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeOnconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and. Valued at $2.2M, ONCO is a micro-cap name in its sector. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
Market Cap
$2.2M
Beta
2.61
P/E (TTM)
0.00
P/E (Fwd)
-0.49
EPS (TTM)
$310.39
EPS (Fwd)
$-0.85
ROE
-105.2%
ROA
-27.0%
Cash
$5.9M
Total Debt
$187,128
Free CF
-$5.9M
52W Change
-99.8%
Annual Financials
Cash vs Debt
Where ONCO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ONCO finished 89.64% below its 150-day moving average ($4.15) and 97.56% below its 200-day moving average ($17.61). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ONCO overbought or oversold?
At the October 20, 2026 close, ONCO's RSI(14) was 11.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Onconetix, Inc. holds $5.9M in cash against $187K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$5.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -105.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Onconetix, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, ONCO has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Onconetix, Inc. and its sector.